Novo Nordisk AS (XTER:NOV)
€ 101.36 0.84 (0.84%) Market Cap: 451.12 Bil Enterprise Value: 448.72 Bil PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 91/100

Q2 2024 Novo Nordisk A/S Earnings Call Transcript

Aug 07, 2024 / 11:00AM GMT
Release Date Price: €110.16 (-6.77%)
Operator

(audio in progress) (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jacob Rode, Head of Investor Relations. Please go ahead, sir.

Jacob Rode;S;Head of Investor Relations
Novo Nordisk A

/-

Thank you. Welcome to this Novo Nordisk earnings call for the first six months of 204. My name is Jacob Martin Wiborg Rode, and I'm the Head of Investor Relations at Novo Nordisk.

With me today, I have CEO of Novo Nordisk, Lars Fruergaard Jørgensen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally, Chief Financial Officer, Karsten Munk Knudsen. All speakers will be available for the Q&A session.

Today's announcement and the slides for this call are available on our website, novonordisk.com. Please note that this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot